


Trial design: Overweight and obese patients with cardiovascular disease (CVD) or multiple CV risk factors were randomized to lorcaserin 10 mg twice daily (n = 6,000) vs. placebo (n = 6,000).



RESULTS

- Major CV events (CV death, myocardial infarction, or stroke: 2.0% per year in the lorcaserin group vs. 2.1% per year in the placebo group (p for noninferiority < 0.001)
- Major CV events, heart failure, or hospitalization for unstable angina or revascularization: 4.1% per year in the lorcaserin group vs. 4.2% per year in the placebo group (p = NS)

CONCLUSIONS

- Among overweight and obese patients with CVD or major risk for CVD, lorcaserin was safe
- Compared with placebo, lorcaserin was not associated with an increase in adverse CV events

Bohula EA, et al. N Engl J Med 2018;379:1107-17



AMERICAN
COLLEGE of
CARDIOLOGY®